HIGHLIGHTS
- who: Admin from the of Internal Medicine, Geisinger Medical Center, USA have published the research: Disseminated Cryptococcal Disease with Skeletal and Pulmonary Involvement 2Paula McKenzie 3Caroline Dillon and 4Amelia Morgan, in the Journal: (JOURNAL)
- what: There is little consensus as to a definitive antifungal regimen.
SUMMARY
Ibrutinib is a Bruton Tyrosine Kinase (BTK) inhibitor approved in 2014 to treat Chronic Lymphocytic Leukemia (CLL). While it has garnered acclaim for its usefulness in lymphoproliferative disease, it has also gathered notoriety due to an alarming amount of reports of Invasive Fungal Infections (IFIs . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.